Philadelphia, PA – According to filings with the U.S. Securities and Exchange Commission, Neuraptive Therapeutics is raising $38,132,939.00 in new funding. Sources indicate as part of senior management Chairman and Chief Executive Officer, Robert Radie played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Neuraptive Therapeutics
Neuraptive Therapeutics is a biotechnology company developing novel therapies to potentially improve outcomes in peripheral nerve injuries, or PNI. We believe our innovations have the potential to improve the quality and speed of recovery of nerve function and sensation for eligible patients who have sustained traumatic injuries or who are undergoing reconstructive surgical procedures by preventing the degeneration of axons distal to injury. NTX-001 has received Fast Track Designation from the United States Food and Drug Administration, and patients are currently enrolling in two Phase 2 multi-center clinical trials. The first trial is for patients with upper extremity peripheral nerve injury and the second trial is for patients with clinical evidence of facial paralysis requiring facial nerve repair from conditions or interventions that have or may result in paralysis. We are also developing nerve-specific microsurgical instruments for use in peripheral nerve surgery.

To learn more about Neuraptive Therapeutics, visit http://www.neuraptive.com/

Contact:
Robert Radie, Chairman and Chief Executive Officer
484-787-3203
https://www.linkedin.com/in/robert-radie-669945b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved